CoChat

Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease

Open access
Mendonça, Clarissa Ferolla, Kuras, Magdalena, Nogueira, Fábio César Sousa, Plá, Indira, Hortobágyi, Tibor, Csiba, László, Palkovits, Miklós, Renner, Éva, Döme, Péter, Marko-Varga, György, Domont, Gilberto B., Rezeli, Melinda · 2019 · Neurobiology of Disease
Cited by 70

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

BACKGROUND Alzheimer's disease (AD) is the most common neurodegenerative disorder. Depositions of amyloid β peptide (Aβ) and tau protein are among the major pathological hallmarks of AD. Aβ and tau burden follows predictable spatial patterns during the progression of AD. Nevertheless, it remains obscure why certain brain regions are more vulnerable than others; to investigate this and dysregulated pathways during AD progression, a mass spectrometry-based proteomics study was performed. METHODS In total 103 tissue samples from regions early (entorhinal and parahippocampal cortices - medial temporal lobe (MTL)) and late affected (temporal and frontal cortices - neocortex) by tau pathology were subjected to label-free quantitative proteomics analysis. RESULTS Considering dysregulated proteins during AD progression, the majority (625 out of 737 proteins) was region specific, while some proteins were shared between regions (101 proteins altered in two areas and 11 proteins altered in three areas). Analogously, many dysregulated pathways during disease progression were exclusive to certain regions, but a few pathways altered in two or more areas. Changes in protein expression indicate that synapse loss occurred in all analyzed regions, while translation dysregulation was preponderant in entorhinal, parahippocampal and frontal cortices. Oxidative phosphorylation impairment was prominent in MTL. Differential proteomic analysis of brain areas in health state (controls) showed higher metabolism and increased expression of AD-related proteins in the MTL compared to the neocortex. In addition, several proteins that differentiate brain regions in control tissue were dysregulated in AD. CONCLUSIONS This work provides the comparison of proteomic changes in brain regions affected by tau pathology at different stages of AD. Although we identified commonly regulated proteins and pathways during disease advancement, we found that the dysregulated processes are predominantly region specific. In addition, a distinct proteomic signature was found between MTL and neocortex in healthy subjects that might be related to AD vulnerability. These findings highlight the need for investigating AD's cascade of events throughout the whole brain and studies spanning more brain areas are required to better understand AD etiology and region vulnerability to disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2019.104509

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 70

Metadata

Authors
Mendonça, C. F., Kuras, M., Nogueira, F. C. S., Plá, I., Hortobágyi, T., Csiba, L., Palkovits, M., Renner, É., Döme, P., Marko-Varga, G., Domont, G. B., & Rezeli, M.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2019-10
Volume
130
Pages
104509
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2949566851
Cited by
70
References
32
FWCI
5.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.nbd.2019.104509
The paper
Mendonça, C. F., Kuras, M., Nogueira, F. C. S., Plá, I., Hortobágyi, T., Csiba, L., Palkovits, M., Renner, É., Döme, P., Marko-Varga, G., Domont, G. B., & Rezeli, M. (2019). Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2019.104509

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.